Oncomine Comprehensive Plus Panel in UAE | AED 26,000 | DHA Licensed Facility

Executive Summary & Core Metrics

This comprehensive genomic profiling test delivers actionable insights for targeted cancer therapy.

99.9% Diagnostic Sensitivity – ISO-certified analytical processing delivering 99.9% diagnostic accuracy.
Secure Medical Courier Solid Tissue Specimen Retrieval – Temperature-controlled transport for FFPE tumor tissue blocks or slides.
Post-Test Clinical Guidance – Telephonic consultation with expert clinicians for genomic report interpretation and therapeutic guidance.
Direct Insurance Billing Verification – Verify direct billing eligibility via WhatsApp at +971 54 548 8731.

Test Overview & Methodology

The Oncomine Comprehensive Plus Panel is a cutting-edge next-generation sequencing (NGS) test that analyzes over 500 cancer-related genes from solid tumor tissue, detecting somatic mutations, copy number variations, gene fusions, and genomic signatures (TMB, MSI) to inform targeted therapy, immunotherapy, and clinical trial eligibility. A valid physician prescription is required. The sample must be an FFPE tumor tissue block or 10 freshly cut unstained sections on positively charged slides. Please coordinate tissue shipment with our pathology logistics team. No medication or supplement restrictions apply for this tissue-based test.

Feature	Our Test – Oncomine Comprehensive Plus	Standard Single-Gene Testing
Methodology	Comprehensive NGS (CGP) – simultaneous analysis of >500 genes	PCR or limited NGS (1–10 genes)
Genomic Profiling	SNVs, indels, CNVs, fusions, TMB, MSI	Selected point mutations only
Therapeutic Actionability	Guides targeted drugs & immunotherapies; clinical trial matching	Limited to few gene-specific drugs
TAT	2–3 weeks	1–2 weeks
Sample Type	FFPE tumor tissue block or 10 unstained slides	Blood or FFPE tissue (limited)

Physician Insight & Safety Protocols

“This comprehensive genomic panel offers a transformative view of each patient's tumor biology. However, genomic findings must always be correlated with histopathology, imaging, and family history to craft a truly personalized and safe treatment plan. It is never a standalone decision tool.” – Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011

Medication Safety Advisory

Never discontinue or modify prescribed medications based solely on genetic test results. Always consult your treating oncologist or prescribing physician before making any therapy changes.

Patient Exclusion Criteria & Emergency Red Flags

Exclusion Criteria: Pregnancy (non-essential testing), minors without legal guardian consent, severely degraded tumor specimen (necrosis >50%), active untreated systemic infection.
Emergency Red Flags: If you develop acute symptoms such as severe pain, bleeding, fever, or rapid clinical deterioration, seek immediate emergency medical care and do not delay for genetic test results.

Patient FAQ & Clinical Guidance

1. What does the Oncomine Comprehensive Plus panel detect?

This NGS panel detects somatic mutations, copy number changes, gene fusions, tumor mutational burden (TMB), and microsatellite instability (MSI) across more than 500 cancer genes. Results guide targeted and immunotherapies.

2. Who should consider this comprehensive genomic panel?

Patients diagnosed with advanced or rare solid tumors seeking therapy guidance, hereditary cancer risk assessment, or clinical trial eligibility.

3. How do I prepare for the test and get my results in the UAE?

No patient preparation is needed beyond providing a tumor tissue specimen; results are delivered in 2–3 weeks with an optional telephonic clinical interpretation session provided by our DHA-licensed physicians.

UAE Regulatory & Data Privacy Adherence

DNA Labs UAE complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability.

DHA Facility License: 1143. ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139). All test results are interpreted by DHA-licensed physicians.

Clinical & Logistical Metadata

Test Name	Oncomine Comprehensive Plus Panel
Price (AED)	26,000
Turnaround Time	2–3 weeks (14–21 calendar days)
Sample Type / Matrix	FFPE tumor tissue block or 10 unstained slides (archival tissue specimen)
Methodology Used	Next-generation sequencing (NGS) – Comprehensive Genomic Profiling (CGP)
ICD-10-CM Code	Z13.79
LOINC Code	81270-9
DHA Facility License & Laboratory Address	License: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

💬 التحقق عبر الواتساب Verify via WhatsApp 📞 Call Team

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians